240 related articles for article (PubMed ID: 12589832)
1. Herpes simplex virus resistance to antiviral drugs.
Morfin F; Thouvenot D
J Clin Virol; 2003 Jan; 26(1):29-37. PubMed ID: 12589832
[TBL] [Abstract][Full Text] [Related]
2. Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1.
Schalkwijk HH; Shewakramani NR; Das K; Andrei G; Snoeck R
Antimicrob Agents Chemother; 2024 May; 68(5):e0011024. PubMed ID: 38619252
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antiviral drug properties of thymidine kinase of herpes B virus using recombinant herpes simplex virus 1.
Nguyen PHA; Fukushi S; Yamada S; Harada S; Yoshikawa T; Kinoshita H; Kawahara M; Ogawa T; Ebihara H; Moi ML; Saijo M
Microbiol Spectr; 2024 Jan; 12(1):e0309123. PubMed ID: 38095468
[TBL] [Abstract][Full Text] [Related]
4. Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.
Griffiths A
Drug Resist Updat; 2011 Dec; 14(6):251-9. PubMed ID: 21940196
[TBL] [Abstract][Full Text] [Related]
5. A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing.
Schalkwijk HH; Georgala A; Gillemot S; Temblador A; Topalis D; Wittnebel S; Andrei G; Snoeck R
J Infect Dis; 2023 Nov; 228(11):1505-1515. PubMed ID: 37224525
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
[TBL] [Abstract][Full Text] [Related]
7. Management of oral herpes simplex virus infections: The problem of resistance. A narrative review.
Piperi E; Papadopoulou E; Georgaki M; Dovrat S; Bar Illan M; Nikitakis NG; Yarom N
Oral Dis; 2024 Apr; 30(3):877-894. PubMed ID: 37279074
[TBL] [Abstract][Full Text] [Related]
8. Large Subunit of the Human Herpes Simplex Virus Terminase as a Promising Target in Design of Anti-Herpesvirus Agents.
Krasnov VP; Andronova VL; Belyavsky AV; Borisevich SS; Galegov GA; Kandarakov OF; Gruzdev DA; Vozdvizhenskaya OA; Levit GL
Molecules; 2023 Oct; 28(21):. PubMed ID: 37959793
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
Bacon TH; Levin MJ; Leary JJ; Sarisky RT; Sutton D
Clin Microbiol Rev; 2003 Jan; 16(1):114-28. PubMed ID: 12525428
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
11. Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections.
Roy S; Sukla S; De A; Biswas S
Sci Rep; 2022 Jan; 12(1):1345. PubMed ID: 35079057
[TBL] [Abstract][Full Text] [Related]
12. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.
Andrei G; Balzarini J; Fiten P; De Clercq E; Opdenakker G; Snoeck R
J Virol; 2005 May; 79(9):5863-9. PubMed ID: 15827202
[TBL] [Abstract][Full Text] [Related]
13. Computational analysis of antiviral drugs using topological descriptors.
Fraz HM; Ali K; Nadeem MF
Comput Biol Med; 2024 Jun; 175():108529. PubMed ID: 38718667
[TBL] [Abstract][Full Text] [Related]
14. Unusual oral presentation of acyclovir-resistant herpes simplex in an allogeneic haematopoietic stem cell transplant recipient.
Saunsbury T; Harte M; Ion D
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969809
[TBL] [Abstract][Full Text] [Related]
15. Amenamevir for treating acyclovir-resistant or refractory herpes simplex virus infection in allogeneic hematopoietic stem cell transplantation recipients: Two case reports.
Sallée L; Souchet L; Boutolleau D; Nguyen S
Int J Antimicrob Agents; 2024 Jun; 63(6):107169. PubMed ID: 38608846
[No Abstract] [Full Text] [Related]
16. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
McMahon MA; Siliciano JD; Lai J; Liu JO; Stivers JT; Siliciano RF; Kohli RM
J Biol Chem; 2008 Nov; 283(46):31289-93. PubMed ID: 18818198
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of human mpox viral DNA replication inhibition by brincidofovir and cidofovir.
Xu Y; Wu Y; Wu X; Zhang Y; Yang Y; Li D; Yang B; Gao K; Zhang Z; Dong C
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132231. PubMed ID: 38735603
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
19. Development of Provesicular Nanodelivery System of Curcumin as a Safe and Effective Antiviral Agent: Statistical Optimization, In Vitro Characterization, and Antiviral Effectiveness.
Badria FA; Abdelaziz AE; Hassan AH; Elgazar AA; Mazyed EA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33271831
[TBL] [Abstract][Full Text] [Related]
20. Structural understanding of non-nucleoside inhibition in an elongating herpesvirus polymerase.
Hayes RP; Heo MR; Mason M; Reid J; Burlein C; Armacost KA; Tellers DM; Raheem I; Shaw AW; Murray E; McKenna PM; Abeywickrema P; Sharma S; Soisson SM; Klein D
Nat Commun; 2021 May; 12(1):3040. PubMed ID: 34031403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
